Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality()

Rivera-Izquierdo, Mario; Valero-Ubierna, María del Carmen; R-delAmo, Juan Luis; Fernández-García, Miguel Ángel; Martínez-Diz, Silvia; Tahery-Mahmoud, Arezu; Rodríguez-Camacho, Marta; Gámiz-Molina, Ana Belén; Barba-Gyengo, Nicolás; Gámez-Baeza, Pablo; Cabrero-Rodríguez, Celia; Guirado-Ruiz, Pedro Antonio; Martín-Romero, Divina Tatiana; Láinez-Ramos-Bossini, Antonio Jesús; Sánchez-Pérez, María Rosa; Mancera-Romero, José; García-Martín, Miguel; Martín-delosReyes, Luis Miguel; Martínez-Ruiz, Virginia; Jiménez-Mejías, Eladio

BACKGROUND AND OBJECTIVES: In the last months great efforts have been developed to evaluate the more efficient therapeutic agents in the management of patients with COVID-19. Currently, no specific drug combination has consistently demonstrated an association with mortality. The aim of this study was to assess the pattern of associations observed between the different in-hospital treatments administered to a series of 238 patients admitted for COVID-19 and their relationship with mortality. METHODS: The electronic medical records of patients that discharged or died from COVID-19 in the Hospital Universitario San Cecilio (Granada, Spain) between March 16 and April 10, 2020 were analysed. From these records, information was obtained on sex, age, comorbidities at admission, clinical information, analytical parameters, imaging tests and empirical treatments used. The outcome variable was the in-hospital mortality. To estimate the associations between the different therapeutic alternatives and the risk of mortality, Hazard Ratios adjusted for age, sex, previous pathologies and severity at discharge were estimated using Cox Regression models. RESULTS: The most frequently used combination of drugs was low molecular weight heparins, hydroxychloroquine, and ritonavir/lopinavir. None of the analysed treatments showed independent association with mortality. The drugs that showed a greater inverse association with mortality were tocilizumab and corticoids. CONCLUSIONS: The observed association patterns are consistent with previous literature. It seems necessary to design randomized controlled clinical trials that evaluate the possible protector effect of tocilizumab and corticoids in the risk of mortality for some subgroups of COVID-19 hospitalized patients.